文献速递消化、代谢与肾脏急症

塞来昔布对比萘普生在合并心血栓疾病和关节炎且上消化道出血后患者中的胃肠道安全性(CONCERN):一项独立于企业的双盲双模拟随机试验

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
PubMed 文献 · Lancet · 2017-04-11
一句话结论对于需同时使用阿司匹林和NSAID的高心血管及胃肠道风险患者,塞来昔布联合质子泵抑制剂较萘普生联合质子泵抑制剂降低18个月内复发性上消化道出血风险,作者认为塞来昔布联合质子泵抑制剂是首选治疗,应避免使用萘普生。

这项独立于企业、双盲双模拟随机试验在香港一家学术医院纳入514例患有关节炎和心血栓疾病、正在使用NSAID并需要同时使用阿司匹林的上消化道出血患者。溃疡愈合后,幽门螺杆菌阴性患者按1:1随机接受塞来昔布100 mg每日两次联合埃索美拉唑20 mg每日一次,或萘普生500 mg每日两次联合埃索美拉唑20 mg每日一次,疗程18个月,所有患者恢复阿司匹林80 mg每日一次。主要终点为18个月内复发性上消化道出血,塞来昔布组累积发生率为5.6%(95%CI 3.3-9.2),萘普生组为12.3%(95%CI 8.8-17.1),p=0.008;粗风险比为0.44(95%CI 0.23-0.82),p=0.010。作者认为,对于需要同时使用阿司匹林和NSAID的高心血管及胃肠道风险患者,塞来昔布联合质子泵抑制剂是降低复发性上消化道出血风险的首选治疗,应避免使用萘普生。

要点

  • 在需要同时使用阿司匹林和NSAID的高心血管及胃肠道风险患者中,塞来昔布100 mg每日两次联合埃索美拉唑20 mg每日一次组18个月内复发性上消化道出血累积发生率为5.6%(95%CI 3.3-9.2),萘普生500 mg每日两次联合埃索美拉唑20 mg每日一次组为12.3%(95%CI 8.8-17.1),p=0.008。
  • 粗风险比为0.44(95%CI 0.23-0.82),p=0.010,塞来昔布联合质子泵抑制剂组复发性上消化道出血风险低于萘普生联合质子泵抑制剂组。
  • 塞来昔布组复发性出血14例(9例胃溃疡和5例十二指肠溃疡),萘普生组31例(25例胃溃疡、3例十二指肠溃疡、1例胃溃疡合并十二指肠溃疡、2例出血性糜烂)。
  • 因不良事件导致停用治疗者,塞来昔布组21例(8%),萘普生组17例(7%);研究期间无治疗相关死亡。
  • 作者认为,对于需要同时使用阿司匹林和NSAID的高心血管及胃肠道风险患者,塞来昔布联合质子泵抑制剂是降低复发性上消化道出血风险的首选治疗,应避免使用萘普生。

适用人群与场景

  • 患有关节炎和心血栓疾病、正在使用NSAID并需要同时使用阿司匹林、表现为上消化道出血的患者。
  • 溃疡愈合后且幽门螺杆菌阴性的患者。

处置流程与药物剂量

  • 溃疡愈合后,幽门螺杆菌阴性患者随机接受口服塞来昔布100 mg每日两次联合埃索美拉唑20 mg每日一次,或口服萘普生500 mg每日两次联合埃索美拉唑20 mg每日一次,疗程18个月。
  • 所有患者恢复阿司匹林80 mg每日一次。

研究设计与关键结果

  • 研究类型:独立于企业、双盲双模拟随机试验;在香港一家学术医院进行;纳入514例患者,塞来昔布组257例,萘普生组257例,均纳入意向性治疗人群。
  • 主要终点:18个月内复发性上消化道出血;塞来昔布组累积发生率5.6%(95%CI 3.3-9.2),萘普生组12.3%(95%CI 8.8-17.1),p=0.008;粗风险比0.44(95%CI 0.23-0.82),p=0.010。
  • 复发性出血事件:塞来昔布组14例(9例胃溃疡和5例十二指肠溃疡),萘普生组31例(25例胃溃疡、3例十二指肠溃疡、1例胃溃疡合并十二指肠溃疡、2例出血性糜烂)。
  • 因不良事件导致停用治疗:塞来昔布组21例(8%),萘普生组17例(7%);研究期间无治疗相关死亡。

证据类型、等级与局限

  • 证据类型:随机对照试验(双盲双模拟)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于需要同时使用阿司匹林和NSAID的高心血管及胃肠道风险患者,作者认为塞来昔布联合质子泵抑制剂是降低复发性上消化道出血风险的首选治疗。
  • 作者认为应避免使用萘普生,尽管其被认为具有心血管安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selective NSAID plus proton-pump inhibitor is superior to a non-selective NSAID plus proton-pump inhibitor for prevention of recurrent ulcer bleeding in concomitant users of aspirin with previous ulcer bleeding.

METHODS: For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin. After ulcer healing, an independent staff member randomly assigned (1:1) patients who were negative for Helicobacter pylori with a computer-generated list of random numbers to receive oral administrations of either celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day or naproxen 500 mg twice per day plus esomeprazole 20 mg once per day for 18 months. All patients resumed aspirin 80 mg once per day. Both patients and investigators were masked to their treatments. The primary endpoint was recurrent upper gastrointestinal bleeding within 18 months. The primary endpoint and secondary safety endpoints were analysed in the modified intention-to-treat population. This study was registered with ClinicalTrials.gov, number NCT00153660.

FINDINGS: Between May 24, 2005, and Nov 28, 2012, we enrolled 514 patients, assigning 257 patients to each study group, all of whom were included in the intention-to-treat population. Recurrent upper gastrointestinal bleeding occurred in 14 patients in the celecoxib group (nine gastric ulcers and five duodenal ulcers) and 31 patients in the naproxen group (25 gastric ulcers, three duodenal ulcers, one gastric ulcer and duodenal ulcer, and two bleeding erosions). The cumulative incidence of recurrent bleeding in 18 months was 5·6% (95% CI 3·3-9·2) in the celecoxib group and 12·3% (8·8-17·1) in the naproxen group (p=0·008; crude hazard ratio 0·44, 95% CI 0·23-0·82; p=0·010). Excluding patients who reached study endpoints, 21 (8%) patients in the celecoxib group and 17 (7%) patients in the naproxen group had adverse events leading to discontinuation of treatment. No treatment-related deaths occurred during the study.

INTERPRETATION: In patients at high risk of both cardiovascular and gastrointestinal events who require concomitant aspirin and NSAID, celecoxib plus proton-pump inhibitor is the preferred treatment to reduce the risk of recurrent upper gastrointestinal bleeding. Naproxen should be avoided despite its perceived cardiovascular safety.

FUNDING: The Research Grant Council of Hong Kong.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017. PMID: 28410791. doi:10.1016/S0140-6736(17)30981-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。